CDK4 and breast cancer: Nonetheless, the recent clinical advancement of dual CDK4/6 inhibitors for treatment of HER2 negative breast cancer has amplified broader interest in exploring the therapeutic potential of the established and understudied CDKs with small-molecule inhibitors9,10.